Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Prostate Cancer

  Free Subscription


02.02.2026

1 Am J Clin Pathol
3 BJU Int
1 BMC Cancer
2 BMC Urol
1 Cancer Imaging
1 Clin Cancer Res
1 Eur Radiol
2 Int J Urol
1 J Clin Lab Anal
1 J Clin Oncol
1 J Natl Cancer Inst
3 J Nucl Med
2 PLoS One
1 Proc Natl Acad Sci U S A
5 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. HUMBLE RM, Paturu R, Xiao H, Yang C, et al
    Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience.
    Am J Clin Pathol. 2026;165:aqaf128.
    PubMed         Abstract available


    BJU Int

  2. KATO T, Yokomizo A, Matsumoto R, Fukuhara H, et al
    Active surveillance for patients with prostate cancer aged >/=75 years: the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study.
    BJU Int. 2026 Jan 29. doi: 10.1111/bju.70156.
    PubMed         Abstract available

  3. KAM J, Hanna B, Jackson S, McCombie S, et al
    Focal therapy using a novel cooled laser device for prostate cancer: early trial results.
    BJU Int. 2026 Jan 28. doi: 10.1111/bju.70150.
    PubMed         Abstract available

  4. AL-HAMMOURI T, Brembilla G, Brizmohun M, Tuazon J, et al
    The 'Comparison of diagnostic accuracy of Luminal Index and standard of care MRI for Accelerated deTEction of prostate cancer' (CLIMATE) trial protocol.
    BJU Int. 2026 Jan 25. doi: 10.1111/bju.70108.
    PubMed         Abstract available


    BMC Cancer

  5. JIANG S, Su S, Wang D
    C21orf2 as a potential regulator of JAK2/STAT3 signaling in prostate cancer cell proliferation and apoptosis: an exploratory study.
    BMC Cancer. 2026 Jan 29. doi: 10.1186/s12885-026-15637.
    PubMed         Abstract available


    BMC Urol

  6. WU K, Ye C, Liu Z, Zhang Y, et al
    Development and external validation of nomograms for predicting prostate cancer and clinically significant prostate cancer in patients with PSA between 4 and 20 ng/mL.
    BMC Urol. 2026 Jan 24. doi: 10.1186/s12894-026-02055.
    PubMed        

  7. YILDIRIM U, Uslu M, Ezer M, Erihan IB, et al
    The potential of real-time ultrasound screen viewing to reduce pain and anxiety symptoms during transperineal prostate biopsy under local anesthesia: a prospective non-randomized observational study.
    BMC Urol. 2025;26:23.
    PubMed         Abstract available


    Cancer Imaging

  8. LIN LP, Cheng XW, Chen J, Li SY, et al
    Prognostic features of biochemical recurrence of prostate cancer following radical prostatectomy based on diffusion kurtosis imaging.
    Cancer Imaging. 2026 Jan 28. doi: 10.1186/s40644-026-00997.
    PubMed        


    Clin Cancer Res

  9. VALENTIN LOPEZ JC, Yu C, Knutson TP, Kobilka A, et al
    Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trial.
    Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-2779.
    PubMed         Abstract available


    Eur Radiol

  10. DELBERGHE F, Li X, van den Kroonenberg DL, Turco S, et al
    Development of a quantitative multiparametric ultrasound and deep learning classifier for the detection of prostate cancer.
    Eur Radiol. 2026 Jan 30. doi: 10.1007/s00330-026-12323.
    PubMed         Abstract available


    Int J Urol

  11. MONCADA I, Krishnappa P, Fraile-Poblador A, Moscatiello P, et al
    A Comparative Study of Simultaneous and Delayed Penile Prosthesis During Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70285.
    PubMed         Abstract available

  12. ISHII N, Yoneyama T, Minakawa S, Konishi S, et al
    Immediate Postoperative cfDNA Elevation Predicts Pain After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70297.
    PubMed         Abstract available


    J Clin Lab Anal

  13. LIU Z, Shan J, Zhang Q, Gao Y, et al
    Diagnostic Efficiency of Age-Adjusted PSAD for Prostate Cancer and Clinically Significant Prostate Cancer: Construction and Nomogram Validation.
    J Clin Lab Anal. 2026 Jan 28:e70135. doi: 10.1002/jcla.70135.
    PubMed         Abstract available


    J Clin Oncol

  14. STISH BJ, Mazza GL, Nauseef JT, Humeniuk MS, et al
    Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
    J Clin Oncol. 2026 Jan 26:JCO2501486. doi: 10.1200/JCO-25-01486.
    PubMed         Abstract available


    J Natl Cancer Inst

  15. DA SILVA M, Fritz J, Elhakeem A, Jochems SHJ, et al
    Weight trajectories throughout adulthood and prostate cancer incidence, aggressiveness, and death in 258,494 men.
    J Natl Cancer Inst. 2026 Jan 23:djag014. doi: 10.1093.
    PubMed         Abstract available


    J Nucl Med

  16. WIDJAJA L, Siegmund SC, Gildehaus FJ, Delker A, et al
    PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [(225)Ac]Ac-PSMA Radiopharmaceutical Therapy.
    J Nucl Med. 2026 Jan 29:jnumed.125.270677. doi: 10.2967/jnumed.125.270677.
    PubMed         Abstract available

  17. CERCI JJ, Fanti S, Lobato EE, Kumar R, et al
    (68)Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study.
    J Nucl Med. 2026 Jan 29:jnumed.125.271173. doi: 10.2967/jnumed.125.271173.
    PubMed         Abstract available

  18. LI Y, Yang J, Chen B, Xiao L, et al
    Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value.
    J Nucl Med. 2026 Jan 29:jnumed.125.271410. doi: 10.2967/jnumed.125.271410.
    PubMed         Abstract available


    PLoS One

  19. KAHNS S, Zedan AH, Aagaard MM, Canto LMD, et al
    Methylation-specific, universal, and highly sensitive identification of ctDNA in prostate cancer by multiplex droplet digital PCR.
    PLoS One. 2026;21:e0340786.
    PubMed         Abstract available

  20. LI J, Lv X, Jiang Y
    Effects of silybin on triptorelin-induced bone metabolic abnormalities in prostate cancer revealed based on TMT-based proteomics.
    PLoS One. 2026;21:e0341064.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  21. TRAPHAGEN NA, Wheeler E, Li R, Akhshi T, et al
    Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2515790122.
    PubMed         Abstract available


    Prostate

  22. REBOUCAS RB, da Costa Souto M, Luiza Jacome Franca Campos A, Monteiro RC, et al
    The Pubovesical Complex-Sparing Laparoscopic Radical Prostatectomy Improves Early Urinary Continence Without Compromising Oncologic Safety: A Prospective, Randomized, and Double-Blinded Clinical Trial.
    Prostate. 2026;86:475-480.
    PubMed         Abstract available

  23. LI YH, Chuang YF, Ou YC, Lin YS, et al
    Cystoscopic ICG-Guided Sentinel Lymph Node Dissection in Robotic Radical Prostatectomy: A Prospective Study.
    Prostate. 2026;86:481-492.
    PubMed         Abstract available

  24. HATAYAMA T, Sekino Y, Kobayashi G, Yukihiro K, et al
    Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis.
    Prostate. 2026 Jan 26. doi: 10.1002/pros.70134.
    PubMed         Abstract available

  25. SIECH C, Bruggemann T, Le QC, Lauer B, et al
    External Validation of the Martini-Klinik Nomogram Predicting the Indication for Adjuvant Radiation Therapy According to EAU Guidelines Among Patients With High-Risk Prostate Cancer After Radical Prostatectomy.
    Prostate. 2026 Jan 29. doi: 10.1002/pros.70135.
    PubMed         Abstract available

  26. FERRARI AC, Chen YH, Rodriguez R, Hudes GR, et al
    Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809).
    Prostate. 2026 Jan 29. doi: 10.1002/pros.70125.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.